Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghazzi, M. N.
Right arrow Articles by Whitcomb, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghazzi, M. N.
Right arrow Articles by Whitcomb, R. W.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 46, Issue 3 433-439, Copyright © 1997 by American Diabetes Association

ARTICLES

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group

MN Ghazzi, JE Perez, TK Antonucci, JH Driscoll, SM Huang, BW Faja and RW Whitcomb
Parke-Davis Pharmaceutical Research, Diabetes and Metabolic Diseases, Ann Arbor, Michigan 48105, USA.

Troglitazone is a thiazolidinedione under development for the treatment of NIDDM and potentially other insulin-resistant disease states. Treatment with troglitazone is associated with an improvement in hyperglycemia, hyperinsulinemia, and insulin-mediated glucose disposal. No significant side effects have been observed in humans. Because of reported cardiac changes in animals treated with drugs of this class, this multicenter 48-week study was conducted to evaluate whether NIDDM patients treated with troglitazone develop any cardiac mass increase or functional impairment. A total of 154 NIDDM patients were randomized to receive troglitazone 800 mg q.d. or glyburide titrated to achieve glycemic control (< or =20 mg b.i.d. or q.d.). Two-dimensional echocardiography and pulsed Doppler were used to measure left ventricular mass index (LVMI), cardiac index (CI), and stroke volume index (SVI). All echocardiograms were performed at each center (baseline, 12, 24, 36, and 48 weeks), recorded on videotape, and forwarded to a blinded central echocardiographic interpreter for analysis. The results showed that LVMI of patients treated with troglitazone was not statistically or clinically different from baseline after 24 or 48 weeks. Statistically significant increases in SVI and CI and a statistically significant decrease in diastolic pressure and estimated peripheral resistance were observed in troglitazone-treated patients. These results were not sex-specific. Glycemic benefits of troglitazone treatment were observed as evidenced by long-term improvement of HbA1c and C-peptide levels. Furthermore, triglycerides were significantly lower, and HDL was significantly higher at weeks 24 and 48. In conclusion, NIDDM patients treated with troglitazone do not show any cardiac mass increase or cardiac function impairment. Conversely, patients on troglitazone benefited from enhanced cardiac output and stroke volume, possibly as a result of decreased peripheral resistance. Treatment with troglitazone appears to have a favorable impact on known cardiovascular risk factors and could potentially lower cardiovascular morbidity in NIDDM patients.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
J. Lindenfeld and F. A. Masoudi
Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome?
J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1705 - 1707.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
H. J. Dargie, P. R. Hildebrandt, G. A.J. Riegger, J. J.V. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P.H. Wilding
A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure
J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1696 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. Boden, C. Homko, M. Mozzoli, M. Zhang, K. Kresge, and P. Cheung
Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 Diabetes: Prevention of Fluid Retention
Diabetes, January 1, 2007; 56(1): 248 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. N. Hodis, W. J. Mack, L. Zheng, Y. Li, M. Torres, D. Sevilla, Y. Stewart, B. Hollen, K. Garcia, P. Alaupovic, et al.
Effect of Peroxisome Proliferator-Activated Receptor {gamma} Agonist Treatment on Subclinical Atherosclerosis in Patients With Insulin-Requiring Type 2 Diabetes
Diabetes Care, July 1, 2006; 29(7): 1545 - 1553.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall, C. J. Rubin, P. Mohideen, J.-M. Ledeine, R. Belder, J. Gross, P. Norwood, M. O'Mahony, K. Sall, G. Sloan, et al.
Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study
Diabetes Care, May 1, 2006; 29(5): 1016 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. I. Vinik, J. Ullal, H. K. Parson, P. M. Barlow, and C. M. Casellini
Pioglitazone Treatment Improves Nitrosative Stress in Type 2 Diabetes
Diabetes Care, April 1, 2006; 29(4): 869 - 876.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen
Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator-Activated Receptor-{gamma} Both Induce Cardiac Hypertrophy in Mice
Circ. Res., August 19, 2005; 97(4): 372 - 379.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. Boden, C. Homko, M. Mozzoli, L. C. Showe, C. Nichols, and P. Cheung
Thiazolidinediones Upregulate Fatty Acid Uptake and Oxidation in Adipose Tissue of Diabetic Patients
Diabetes, March 1, 2005; 54(3): 880 - 885.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
Circulation, February 8, 2005; 111(5): 583 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Choi, S.-K. Kim, S.-H. Choi, Y.-G. Ko, C.-W. Ahn, Y. Jang, S.-K. Lim, H.-C. Lee, and B.-S. Cha
Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
Diabetes Care, November 1, 2004; 27(11): 2654 - 2660.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Guan
Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome
J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What is the cause and effect?
Diabetes Care, September 1, 2004; 27(9): 2253 - 2259.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. E. Akiyama, G. Lambert, C. J. Nicol, K. Matsusue, J. M. Peters, H. B. Brewer Jr., and F. J. Gonzalez
Peroxisome Proliferator-activated Receptor {beta}/{delta} Regulates Very Low Density Lipoprotein Production and Catabolism in Mice on a Western Diet
J. Biol. Chem., May 14, 2004; 279(20): 20874 - 20881.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
N. Singh
Rosiglitazone and Heart Failure: Long-Term Vigilance
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 21 - 25.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association
Diabetes Care, January 1, 2004; 27(1): 256 - 263.
[Full Text] [PDF]

Home page
 CirculationHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association
Circulation, December 9, 2003; 108(23): 2941 - 2948.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. T. Hurst and R. W. Lee
Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management
Ann Intern Med, November 18, 2003; 139(10): 824 - 834.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Legro, R. Azziz, D. Ehrmann, A. G. Fereshetian, M. O'Keefe, and M. N. Ghazzi
Minimal Response of Circulating Lipids in Women with Polycystic Ovary Syndrome to Improvement in Insulin Sensitivity with Troglitazone
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5137 - 5144.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Cabrero, M. Jove, A. Planavila, M. Merlos, J. C. Laguna, and M. Vazquez-Carrera
Down-Regulation of Acyl-CoA Oxidase Gene Expression in Heart of Troglitazone-Treated Mice through a Mechanism Involving Chicken Ovalbumin Upstream Promoter Transcription Factor II
Mol. Pharmacol., September 1, 2003; 64(3): 764 - 772.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Liang, F. Wang, S. Zhang, and D. G. Gardner
Peroxisome Proliferator Activated Receptor (PPAR){alpha} Agonists Inhibit Hypertrophy of Neonatal Rat Cardiac Myocytes
Endocrinology, September 1, 2003; 144(9): 4187 - 4194.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. B. Meigs, P. W.F. Wilson, D. M. Nathan, R. B. D'Agostino Sr., K. Williams, and S. M. Haffner
Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies
Diabetes, August 1, 2003; 52(8): 2160 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
F. A. Masoudi, Y. Wang, S. E. Inzucchi, J. F. Setaro, E. P. Havranek, J. M. Foody, and H. M. Krumholz
Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure
JAMA, July 2, 2003; 290(1): 81 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
V. R. Aroda and R. R. Henry
Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease
Diabetes Spectr, April 1, 2003; 16(2): 120 - 125.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C.-H. Wang, R. D. Weisel, P. P. Liu, P. W.M. Fedak, and S. Verma
Glitazones and Heart Failure: Critical Appraisal for the Clinician
Circulation, March 18, 2003; 107(10): 1350 - 1354.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. St. John Sutton, M. Rendell, P. Dandona, J. F. Dole, K. Murphy, R. Patwardhan, J. Patel, and M. Freed
A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes
Diabetes Care, November 1, 2002; 25(11): 2058 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
J D Tugwood and C T Montague
Biology and toxicology of PPARg ligands
Human and Experimental Toxicology, August 1, 2002; 21(8): 429 - 437.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
J. M. Miles, L. Leiter, P. Hollander, T. Wadden, J. W. Anderson, M. Doyle, J. Foreyt, L. Aronne, and S. Klein
Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin
Diabetes Care, July 1, 2002; 25(7): 1123 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. E. Akiyama, S. Sakai, G. Lambert, C. J. Nicol, K. Matsusue, S. Pimprale, Y.-H. Lee, M. Ricote, C. K. Glass, H. B. Brewer Jr., et al.
Conditional Disruption of the Peroxisome Proliferator-Activated Receptor {gamma} Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux
Mol. Cell. Biol., April 15, 2002; 22(8): 2607 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Sugawara, A. Uruno, M. Kudo, Y. Ikeda, K. Sato, Y. Taniyama, S. Ito, and K. Takeuchi
Transcription Suppression of Thromboxane Receptor Gene by Peroxisome Proliferator-activated Receptor-gamma via an Interaction with Sp1 in Vascular Smooth Muscle Cells
J. Biol. Chem., March 15, 2002; 277(12): 9676 - 9683.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Frey and E. N. Olson
Modulating Cardiac Hypertrophy by Manipulating Myocardial Lipid Metabolism?
Circulation, March 12, 2002; 105(10): 1152 - 1154.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
N. V. Chu, A. P. S. Kong, D. D. Kim, D. Armstrong, S. Baxi, R. Deutsch, M. Caulfield, S. R. Mudaliar, R. Reitz, R. R. Henry, et al.
Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Diabetes Care, March 1, 2002; 25(3): 542 - 549.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Arima, K. Kohagura, K. Takeuchi, Y. Taniyama, A. Sugawara, Y. Ikeda, M. Abe, K. Omata, and S. Ito
Biphasic Vasodilator Action of Troglitazone on the Renal Microcirculation
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 342 - 349.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Yamamoto, R. Ohki, R. T. Lee, U. Ikeda, and K. Shimada
Peroxisome Proliferator-Activated Receptor {gamma} Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes
Circulation, October 2, 2001; 104(14): 1670 - 1675.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. I. Vinik, T. Erbas, T. S. Park, K. B. Stansberry, J. A. Scanelli, and G. L. Pittenger
Dermal Neurovascular Dysfunction in Type 2 Diabetes
Diabetes Care, August 1, 2001; 24(8): 1468 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Sugawara, K. Takeuchi, A. Uruno, Y. Ikeda, S. Arima, M. Kudo, K. Sato, Y. Taniyama, and S. Ito
Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-{{gamma}} in Vascular Smooth Muscle Cells
Endocrinology, July 1, 2001; 142(7): 3125 - 3134.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
W. A. Hsueh, S. Jackson, and R. E. Law
Control of Vascular Cell Proliferation and Migration by PPAR-{gamma}: A new approach to the macrovascular complications of diabetes
Diabetes Care, February 1, 2001; 24(2): 392 - 397.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca
Nonhypoglycemic Effects of Thiazolidinediones
Ann Intern Med, January 2, 2001; 134(1): 61 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring
Pathophysiology and Pharmacological Treatment of Insulin Resistance
Endocr. Rev., December 1, 2000; 21(6): 585 - 618.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
E. Arioglu, J. Duncan-Morin, N. Sebring, K. I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D. E. Kleiner, J. Reynolds, A. Premkumar, et al.
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Ann Intern Med, August 15, 2000; 133(4): 263 - 274.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Zhu, L. Lu, Y. Xu, and G. G. Schwartz
Troglitazone Improves Recovery of Left Ventricular Function After Regional Ischemia in Pigs
Circulation, March 14, 2000; 101(10): 1165 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. A. DeFronzo
Pharmacologic Therapy for Type 2 Diabetes Mellitus
Ann Intern Med, August 17, 1999; 131(4): 281 - 303.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. Nakajima, K. Iwasawa, H. Oonuma, H. Imuta, H. Hazama, M. Asano, T. Morita, F. Nakamura, J.-i. Suzuki, S. Suzuki, et al.
Troglitazone Inhibits Voltage-Dependent Calcium Currents in Guinea Pig Cardiac Myocytes
Circulation, June 8, 1999; 99(22): 2942 - 2950.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. C. Turner, C. A. Cull, V. Frighi, R. R. Holman, and for the UK Prospective Diabetes Study Group
Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
JAMA, June 2, 1999; 281(21): 2005 - 2012.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Y. Nishimoto, Y. Miyazaki, Y. Toki, R. Murakami, M. Shinoda, A. Fukushima, and H. Kanayama
Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina
J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1624 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
T. W. Kurtz and D. G. Gardner
Transcription-Modulating Drugs : A New Frontier in the Treatment of Essential Hypertension
Hypertension, September 1, 1998; 32(3): 380 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
M. P. Stern
The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes
Arch Fam Med, March 1, 1998; 7(2): 155 - 162.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.